NCT00731250View on ClinicalTrials.gov

A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 22, 2008

Primary Completion Date

March 1, 2009

Study Completion Date

March 31, 2009

Conditions
Rhinitis
Interventions
DRUG

SB-705498

Subjects will be administered a single dose of 400 mg SB-705498

DRUG

Placebo

Subjects will be administered SB-705498 matching placebo tablets

OTHER

Caspaicin

Subjects will be challenged with 0.5 µg, 5.0 µg and 50 µg intranasal dose

Trial Locations (1)

1105 AZ

GSK Investigational Site, Amsterdam

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY